Panaxia Labs Israel Ltd. and its German partner, Neuraxpharm announced the receipt of regulatory permit from the German Authorities, for marketing and distribution of medical cannabis extracts for inhalation. Panaxia and Neuraxpharm will be the first ever companies to market advanced products of this kind in Europe in general and in Germany in particular, as well as being the exclusive companies in Europe that have a regulatory permit for the marketing of medical cannabis tablets in France, in addition of the marketing permits for medical cannabis oils in Germany and France. The inhalation extract, which will be marketed in Germany under the joint brand Naxiva-Panaxol, is manufactured by Panaxia in accordance with the EU-GMP standard under strict pharmaceutical regulations according to clinical knowledge and methods developed by the company. The marketing permit allows Neuraxpharm, Panaxia's strategic partner, to import the products, distribute it to pharmacies, and market to physicians qualified to issue prescriptions for medical cannabis products to patients for a various range of medical indications,. In addition, on top of the series of products currently approved for marketing, as part of the strategic collaboration with Neuraxpharm, applications are due to be submitted in the near future for registration and marketing of other advanced products developed by Panaxia, including capsules and other products.